Adage Capital Partners’s Aratana Therapeutics, Inc. PETX Stock Holding History

Adage Capital Partners’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-775,000	Closed	-$4.9M	–	745
2016 Q2	$4.9M	Sell	775,000 -25,000	-3%	-$161K	0.01%	591
2016 Q1	$4.42M	Hold	800,000	–	–	0.01%	612
2015 Q4	$4.46M	Buy	800,000 +100,000	+14%	+$661K	0.01%	610
2015 Q3	$5.92M	Sell	700,000 -350,000	-33%	-$5.92M	0.02%	597
2015 Q2	$15.9M	Sell	1,050,000 -150,000	-13%	-$2.17M	0.04%	463
2015 Q1	$19.2M	Sell	1,200,000 -100,000	-8%	-$1.78M	0.05%	430
2014 Q4	$23.2M	Sell	1,300,000 -275,000	-17%	-$3.43M	0.06%	375
2014 Q3	$15.8M	Buy	1,575,000 +300,000	+24%	+$3.64M	0.04%	445
2014 Q2	$19.9M	Hold	1,275,000	–	–	0.05%	398
2014 Q1	$23.7M	Hold	1,275,000	–	–	0.06%	347
2013 Q4	$24.4M	Buy	1,275,000 +275,000	+28%	+$5.58M	0.06%	355
2013 Q3	$16.3M	Hold	1,000,000	–	–	0.05%	411
2013 Q2	$7.56M	Buy	+1,000,000	New	+$7.91M	0.02%	541

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Adage Capital Partners's PETX Position: Q3 2016 in Review

Adage Capital Partners sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 775,000 shares — an estimated $4.9M sold.

Adage Capital Partners first reported a position in PETX in Q2 2013 and held it in 13 quarters. The position peaked at $24.4M in Q4 2013. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

Adage Capital Partners reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Adage Capital Partners sold 775,000 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $4.9M.
Adage Capital Partners first reported a position in Aratana Therapeutics, Inc. in Q2 2013 and held it in 13 quarters.
Adage Capital Partners's Aratana Therapeutics, Inc. position peaked at $24.4M in Q4 2013.
128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on Adage Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.